The respiratory research team at Bradford Teaching Hospitals has put itself on the map after recruiting European and global-first patients in two pioneering medical trials.
The trust says that thanks to a renowned international reputation in respiratory medicine, pharmaceutical giant GSK has chosen the Bradford Institute for Health Research (BIHR) to be the first unit worldwide to test its new vaccine for Chronic Obstructive Pulmonary Disease (COPD) patients.
The multi-centre trial aims to assess whether the vaccine offers protection against a bacterium which commonly causes a worsening in the condition of patients with COPD.
The team have also recruited a Europe-first patient in the Andhi study into severe asthma.
Dr Dinesh Saralaya, Consultant Respiratory Physician and Associate Director of Research at BIHR, said: “In this study there will be 1,000 patients recruited worldwide, and we will recruit between three and five patients.
“Our Clinical Trails Unit has recruited the first patient in the whole of Europe which is a big achievement. They have chosen Bradford because of our reputation for recruiting very well into several asthma trials in the past. But support from our research and development department has helped us achieve this.”
£8.5m Plan Approved to Transform Blackburn Church into Creative Hub
£1.9m Investment Plan for Pools, Museums and Family Hubs
Six Charged After County Lines Raids in Calderdale and Bradford
Tribute paid to hospital radio legend Patrick Murphy
Bradford nurseries recognised with elite ‘900 Club’ award
Muslim Aid Launches Winter Support for Vulnerable Communities
30 Years of Clean-Ups: Britain’s Largest Muslim Youth Group Takes to the Streets on New Year’s Day
Legal Show
The Golden Era
Remix Saturdays
Alim OnAir